Please use this identifier to cite or link to this item: https://scholarhub.balamand.edu.lb/handle/uob/6001
Title: Carbapenemase Inhibitors: Updates on Developments in 2021
Authors: Zerdan, Maroun Bou
Hassan, Sally Al
Shaker, Waleed
Hajjar, Rayan El
Allam, Sabine
Zerdan, Morgan Bou
Naji, Amal
Zeineddine, Nabil
Affiliations: Faculty of Medicine 
Keywords: Carbapenem resistance
Carbapenemase inhibitors
Pathogens
Issue Date: 2022
Part of: Journal of Clinical Medicine Research
Volume: 14
Issue: 7
Start page: 251
End page: 259
Abstract: 
Carbapenem resistance, an emerging global health problem, compromises the treatment of infections caused by nosocomial pathogens. Preclinical and clinical trials demonstrate that a new generation of carbapenemases inhibitors, together with the recently approved avi-bactam, relebactam and vaborbactam, would address this resistance. Our review summarizes the latest developments related to carbap-enemase inhibitors synthesized to date, as well as their spectrum of activity and their current stage of development. A particular focus will be on β-lactam/β-lactamase inhibitor combinations that could potentially be used to treat infections caused by carbapenemase-producer pathogens. These new combinations mark a critical step forward the fight against antimicrobial resistance.
URI: https://scholarhub.balamand.edu.lb/handle/uob/6001
ISSN: 19183003
DOI: 10.14740/jocmr4764
Open URL: Link to full text
Type: Journal Article
Appears in Collections:Faculty of Medicine

Show full item record

Record view(s)

9
checked on Feb 6, 2023

Google ScholarTM

Check

Dimensions Altmetric

Dimensions Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.